Mark Meyers
University of Wisconsin-Madison
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark Meyers.
Mutation Research | 1996
David A. Boothman; Mark Meyers; Eric Odegaard; Meizhi Wang
Adaptive survival responses (ASRs) are observed when cells become more resistant to a high dose of a cytotoxic agent after repeated low dose exposures to that agent or another genotoxic agent. Confluent (G0/G1) human normal (GM2936B, GM2937A, AG2603, IMR-90), cancer-prone (XPV2359), and neoplastic (U1-Mel, HEp-2, HTB-152) cells were primed with repeated low doses of X-rays (ranging from 0.05-10 cGy/day for 4 days), then challenged with a high dose (290-450 cGy) on day 5. U1-Mel and HEp-2 cells showed greater than 2-fold transient survival enhancement when primed with 1-10 cGy. ASRs in U1-Mel or HEp-2 cells were blocked by cycloheximide or actinomycin D. Increases in cyclins A and D1 mRNAs were noted in primed compared to unirradiated U1-Mel and HEp-2 cells; however, only cyclin A protein levels increased. Cyclin D1 and proliferating cell nuclear antigen (PCNA) protein levels were constitutively elevated in HEp-2 and U1-Mel cells, compared to the other human normal and neoplastic cells examined, and were not altered by low or high doses of radiation. Low dose primed U1-Mel cells entered S-phase 4-6 h faster than unprimed U1-Mel cells upon low-density replating. Similar responses in terms of survival recovery, transcript and protein induction, and altered cell cycle regulation were not observed in the other human normal, cancer-prone or neoplastic cells examined. We hypothesize that only certain human cells can adapt to ionizing radiation by progressing to a point later in G1 (the A point) where DNA repair processes and radioresistance can be induced. ASRs in human cells correlated well with constitutively elevated levels of PCNA and cyclin D1, as well as inducibility of cyclin A. We propose that a protein complex composed of cyclin D1, PCNA, and possibly cyclin A may play a role in cell cycle regulation and DNA repair, which determine ASRs in human cells.
Oncogene | 2003
Mark Meyers; Arlene Hwang; Mark W. Wagner; Andrew J Bruening; Martina L. Veigl; W. David Sedwick; David A. Boothman
The phenomenon of damage tolerance, whereby cells incur DNA lesions that are nonlethal, largely ignored, but highly mutagenic, appears to play a key role in carcinogenesis. Typically, these lesions are generated by alkylation of DNA or incorporation of base analogues. This tolerance is usually a result of the loss of specific DNA repair processes, most often DNA mismatch repair (MMR). The availability of genetically matched MMR-deficient and -corrected cell systems allows dissection of the consequences of this unrepaired damage in carcinogenesis as well as the elucidation of cell cycle checkpoint responses and cell death consequences. Recent data indicate that MMR plays an important role in detecting damage caused by fluorinated pyrimidines (FPs) and represents a repair system that is probably not the primary system for detecting damage caused by these agents, but may be an important system for correcting key mutagenic lesions that could initiate carcinogenesis. In fact, clinical studies have shown that there is no benefit of FP-based adjuvant chemotherapy in colon cancer patients exhibiting microsatellite instability, a hallmark of MMR deficiency. MMR-mediated damage tolerance and futile cycle repair processes are discussed, as well as possible strategies using FPs to exploit these systems for improved anticancer therapy.
Radiation Research | 1994
Walter M. Sahijdak; Chin-Rang Yang; Jeffrey S. Zuckerman; Mark Meyers; David A. Boothman
We analyzed alterations in transcription factor binding to specific, known promoter DNA consensus sequences between irradiated and unirradiated radioresistant human melanoma (U1-Mel) cells. The goal of this study was to begin to investigate which transcription factors and DNA-binding sites are responsible for the induction of specific transcripts and proteins after ionizing radiation (Boothman et al., Proc. Natl. Acad. Sci. USA 90, 7200, 1993). Transcription factor binding was observed using DNA band-shift assays and oligonucleotide competition analyses. Confluence-arrested U1-Mel cells were irradiated (4.5 Gy) and harvested at 4 h. Double-stranded oligonucleotides containing known DNA-binding consensus sites for specific transcription factors were used. Increased DNA-binding activity after ionizing radiation was noted with oligonucleotides containing the CREB, NF-kappa B and Sp1 consensus sites. Increased DNA binding activity after ionizing radiation was noted with oligonucleotides containing the CREB, NF-kappa B and Sp1 consensus sites. No changes in protein binding to AP-1, AP-2, AP-3 or CTF/NF1, GRE or Oct-1 consensus sequences were noted. X-ray activation of select transcription factors, which bind certain consensus sites in promoters, may cause specific induction or repression of gene transcription.
Cancer Research | 2001
Mark Meyers; Mark W. Wagner; Hwa-Shin Hwang; Timothy J. Kinsella; David A. Boothman
Cancer Research | 1998
Thomas W. Davis; Carmell Wilson-Van Patten; Mark Meyers; Keith A. Kunugi; Scott Cuthill; Catherine A. Reznikoff; Christopher A. Garces; C. Richard Boland; Timothy J. Kinsella; Richard Fishel; David A. Boothman
Journal of Biological Chemistry | 2005
Mark Meyers; Mark W. Wagner; Anthony Mazurek; Christoph Schmutte; Richard Fishel; David A. Boothman
Cancer Research | 1997
Charles L. Limoli; Mark I. Kaplan; James Corcoran; Mark Meyers; David A. Boothman; William F. Morgan
Cancer Research | 1997
Mark Meyers; Maria Theodosiou; Samir Acharya; Eric Odegaard; Teresa Wilson; Janet E. Lewis; Thomas W. Davis; Carmell Wilson-Van Patten; Richard Fishel; David A. Boothman
Environmental and Molecular Mutagenesis | 2004
Mark Meyers; Arlene Hwang; Mark W. Wagner; David A. Boothman
Cancer Research | 1999
Suzanne E. Berry; Christopher A. Garces; Hwa Shin Hwang; Keith A. Kunugi; Mark Meyers; Thomas W. Davis; David A. Boothman; Timothy J. Kinsella